Nykode Therapeutics Asa · OSL:NYKD
Nykode Therapeutics Asa — DNB Nordic Healthcare Conference 2023
29 slides from Nykode Therapeutics Asa's conference presentation, Dec 14, 2023
Slide 1: DNB Nordic Healthcare Conference
DNB Nordic Healthcare Conference Oslo, December 14, 2023
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: Global leader in antigen presenting cell (APC)-targeted immunotherapy technology
Global leader in antigen presenting cell (APC)-targeted immunotherapy technology NYKODE THERAPEUTICS (NYKD-OL, MKT CAP ~$535M1) Differentiated immunotherapies targeting antigens to Antigen-Presenting Cell (APC) to direct tailor-made immune responses with focus on oncology and autoimmune diseases Str
Slide 4: Rich and diversified pipeline
Rich and diversified pipeline Upcoming Asset Indication Rights Preclinical Phase 1 Phase 2 Phase 3 Catalyst Oncology 1 Initiate trial HPV16+ cervical cancer (Q4 2023) 2 Dose level VB10.16 HPV16+ head and neck cancer recommendation (H2 2024) 2 Off-the-shelf HPV16+ locally advanced Protocol in cervica
Slide 5: Vaccibody vaccine induces a rapid, robust and long-lasting CD8 T cell response against cancer cells
Vaccibody vaccine induces a rapid, robust and long-lasting CD8 T cell response against cancer cells MECHANISM OF ACTION – T CELL INDUCTION Nykode Therapeutics | DNB Nordic Healthcare Conference| Non-confidential 5
Slide 6: VB10.16 in HPV16+ cancers
VB10.16 in HPV16+ cancers Nykode Therapeutics | DNB Nordic Healthcare Conference| Non-confidential 6
Slide 7: VB10.16: Therapeutic vaccine candidate for HPV16+ cancers
VB10.16: Therapeutic vaccine candidate for HPV16+ cancers Targeting unit Off-the-shelf therapeutic cancer DNA vaccine CCL3L1 against HPV16 induced malignancies HPV16 is the most prevalent oncogenic HPV strain VB10.16 Targeting the cancer-specific full-length HPV16 E7 and E6 Off-the-shelf vaccine
Slide 8: HPV16+ cervical cancer is a significant unmet need
HPV16+ cervical cancer is a significant unmet need Cervical cancer incidence worldwide ~130,000 new HPV16+ cancer cases per year • 4th most common cancer in (U.S. and Europe1) women worldwide • 4th leading cause of cancer- 23% related death • Prognosis is poor for recurrent and/or metastatic Anal/Vu
Slide 9: HPV+ cancer incidence is expected to increase despite prophylactic HPV vaccination
HPV+ cancer incidence is expected to increase despite prophylactic HPV vaccination U.S. + EU5 + China + Japan HPV+ CERVICAL CANCER HPV+ HNSCC DIAGNOSED INCIDENT CASES1 DIAGNOSED INCIDENT CASES2 +74% 222,412 163,982 +65% 128,051 112,081 99,250 67,794 2010 2020 2030 2010 2020 2030 1 GlobalData Cervica
Slide 10: VB10.16 C-02 data compare strongly to CPI monotherapy as well as expected SoC in 2L r/m cervical cancer
VB10.16 C-02 data compare strongly to CPI monotherapy as well as expected SoC in 2L r/m cervical cancer CPI Monotherapy in r/m CC VB10.16 plus Atezolizumab in Pembrolizumab in Cemiplimab in Tisotumab vedotin Endpoint atezolizumab PD-L1+††† PD-L1+** PD-L1+ †† (PD-L1 agnostic) ‡ ‡ in PD-L1+ Skyscraper
Slide 11: Maximizing shareholder value by diversifying offerings and broadening therapeutic scope
Maximizing shareholder value by diversifying offerings and broadening therapeutic scope Building a cancer vaccine franchise following strong clinical validation Validation Today Future Opportunities Adjuvant Settings Move earlier to expand patient population and Indication Expansions explore long-te
Slide 12: Creating a portfolio of targeted vaccines for HPV16+ cancers
Creating a portfolio of targeted vaccines for HPV16+ cancers VB10.16 portfolio C-02 C-03 C-04 C-05 r/m head and neck r/m Cervical Cancer, ≥2L r/m Cervical Cancer, Locally Advanced Indication cancer (HNSCC), PD-L1+, 2L Cervical Cancer (LACC) PD-L1+, 1L Up to 9 mg in 3 mg in combination with combinati
Slide 13: VB10.NEO Individualized cancer vaccine
VB10.NEO Individualized cancer vaccine Nykode Therapeutics | DNB Nordic Healthcare Conference| Non-confidential 13
Slide 14: VB10.NEO: Nykode's individualized cancer vaccine
VB10.NEO: Nykode’s individualized cancer vaccine Broad clinical experience 2 clinical trials in more than 10 cancer indications in recurrent metastatic setting Promising immunogenicity data VB10.NEO Broad and durable T cell responses in the Fully individualized vaccine against the clinic multipl
Slide 15: VB10.NEO programs
VB10.NEO programs Safety clearance of 9 mg dose with no safety concerns and no dose limiting toxicities observed N-01 N-02 r/m Melanoma, non-small cell lung cancer (NSCLC), clear renal cell carcinoma, urothelial Indication r/m cancer, covering more than ten indications cancer or squamous cell carcin
Slide 16: Broad and durable neoantigen-specific T cell responses
Broad and durable neoantigen-specific T cell responses DURABLE NEO-AG SPECIFIC T CELL BROAD T CELL RESPONSES IN ALL PATIENTS RESPONSES, ALSO POST VACCINATION Nykode Therapeutics | DNB Nordic Healthcare Conference| Non-confidential 16
Slide 17: NYK011: Vaccine aimed at reducing the burden of colorectal cancer
NYK011: Vaccine aimed at reducing the burden of colorectal cancer Nykode Therapeutics | DNB Nordic Healthcare Conference| Non-confidential 17
Slide 18: Pipeline expansion aims at addressing patients ranging from high-risk pre-cancerous polyps to colorectal cancer
Pipeline expansion aims at addressing patients ranging from high-risk pre-cancerous polyps to colorectal cancer • Colorectal cancer develops from premalignant polyps on the colon or rectum’s mucosal surface • Disease development and screening programs Broad patient population represent an opportunit
Slide 19: Potential first-in-class program built on Nykode's unique technology
Potential first-in-class program built on Nykode’s unique technology creating customized immune responses • Potential first-in-class oncology vaccine program based on careful selection and novel combination of tumor- associated antigens (TAA) • Leveraging Nykode’s expertise to elicit strong and broa
Slide 20: Autoimmunity and further platform potential
Autoimmunity and further platform potential Nykode Therapeutics | DNB Nordic Healthcare Conference| Non-confidential 20
Slide 21: Induction of antigen specific tolerance can be achieved by targeting disease causing epitopes to tolerogenic APCs
Induction of antigen specific tolerance can be achieved by targeting disease causing epitopes to tolerogenic APCs MECHANISM OF ACTION – TOLERANCE INDUCTION (INVERSE VACCINATION) Cells transfected with DNA plasmid vaccine CD4+ Treg Tol APC CD4+ Treg Tol APC Effector T Effector T cell cell Cells encod
Slide 22: Low dose prevent MS disease symptoms, with a dose-dependent decrease in disease associated cytokines
Low dose prevent MS disease symptoms, with a dose-dependent decrease in disease associated cytokines differentiated from Ag alone EAE MODEL Daily clinical scores day -7 day -3 day 0 day 15 Immune parameter read-out at day 15 (at peak of disease) Disease Termination and induction immune analyses MOG(
Slide 23: DNA vaccination targeting tolerogenic APCs prevents type 1 diabetes in a spontaneous mice model
DNA vaccination with Vaccibody targeting tolerogenic APCs prevents type 1 diabetes in a spontaneous mice model Type 1 diabetes is an autoimmune disease where the immune system attacks insulin producing cells in the pancreas Day 0 day 7 day 14 The Non-Obese Diabetic (NOD) model is a mouse diabetes mo
Slide 24: Nykode's APC targeting technology leads to faster, stronger and broader T cell responses in mRNA vaccines
NYKODE’S TECH IMPROVES Nykode’s APC targeting technology MRNA VACCINES leads to faster, stronger and broader T cell responses in mRNA vaccines • Preclinical data shows that using APC targeted neoepitope vaccines with mRNA-LNP, whether delivered via DNA or mRNA, leads to stronger and broader T cell r
Slide 25: Financial overview & outlook
Financial overview & outlook Nykode Therapeutics | DNB Nordic Healthcare Conference| Non-confidential 25
Slide 26: Strong financial foundation for achieving our vision
Strong financial foundation for achieving our vision Cash position of $159m end Q3 2023 Financially well positioned to execute the Company’s strategy over the next years Nykode continues to explore a potential listing on the Nasdaq Global Market in the United States Nykode Therapeutics | DNB Nor
Slide 27: Other events
Other events Private placement Tax matter Norwegian Tax Authorities (NTA) reiterated Successfully raised $45m in private placement their position that upfront payments received Aim to broaden the existing shareholder base under a license agreement entered into in with international investors a
Slide 28: Upcoming milestones
Upcoming milestones Q4 VB10.16 Initiate potentially registrational VB-C-04 trial in the U.S. in patients with 2023 Cervical Cancer recurrent/metastatic disease and PD-L1 positive tumors Announced expansion of oncology pipeline with preclinical program aimed to reduce ✓ Q4 Undisclosed 2023 Oncology t
Slide 29: Unlocking the future of medicine
UNLOCKING THE FUTURE OF MEDICINE Contact: Alexandra Deschner Head of Investor Relations IR@nykode.com Nykode Therapeutics | DNB Nordic Healthcare Conference| Non-confidential
Nykode Therapeutics — DNB Nordic Healthcare Conference 2023 on 6ix